An Akkermansia muciniphila strain marketed by Vidya as NuGensia was found to support measures of metabolic health in adults with prediabetes, in a clinical study published in ECronicon.

The trial enrolled 60 adults between the ages of 31 and 60 with prediabetes, randomized to receive either NuGensia at 10 billion CFU or a placebo once daily for 60 days. After the treatment period, participants showed statistically significant reductions in fasting and postprandial blood glucose, HbA1c, and triglycerides compared to placebo. Significant improvements were also observed in body weight, BMI, waist circumference, and diastolic blood pressure. The ingredient was safe and well-tolerated, with no treatment-related adverse events.

“These findings establish Akkermansia muciniphila as a clinically validated, next-generation probiotic for metabolic health, offering a natural and effective strategy to support glucose balance, weight management, and overall metabolic well-being,” said Subhendu Nayak, director of probiotics R&D at Vidya.

NuGensia is built on Vidya’s patent-pending delivery system, which uses a starch-based protective shell to shield the live probiotic from oxygen exposure during production and storage, overcoming a key stability challenge that has historically limited Akkermansia’s commercial viability as an ingredient.